Parry SRL
1.1 FTEThe score of Parry shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +7 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Parry's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jul 2026
- Year ended 31 Dec 2024filed on 18 Aug 2025
- Year ended 31 Dec 2023filed on 26 Jul 2024
- Year ended 31 Dec 2022filed on 26 Jun 2023
- Year ended 31 Dec 2021filed on 20 Jul 2022
Parry's financial analysis
- Solvency-1.4%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Parry
Parry's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0880.161.865
- VAT number
- BE0880161865
- Peppol
- Registered · 0208:0880161865 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Mar 2006
- Registered office
- 1030 Schaerbeek
- Size
- Micro · 1.1 FTE
- Latest accounts
- 2025 · filed on 29 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Parry (SRL) has been based in Schaerbeek since 2006, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 11,442 € and equity of −3,135 €; its revenue is not published. With 1.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -1.4%, below the median of its sector (37.8%).
Companies similar to Parry
Companies in the same business, of comparable size and area, outside its group.
- LE Lumeçon Retail sale of pharmaceutical products Brussels · balance sheet 213,394 €
- Lmedication Retail sale of pharmaceutical products Fleurus · balance sheet 228,494 €
- Apotheek DE Gaper Retail sale of pharmaceutical products Mortsel · balance sheet 228,107 €
- Pharmacie Defrance Retail sale of pharmaceutical products Jette · balance sheet 229,204 €
- Pharmaphie EVG Retail sale of pharmaceutical products Evergem · balance sheet 229,312 €
- Farmacare Retail sale of pharmaceutical products Aalst · balance sheet 226,083 €
- Jufarma Retail sale of pharmaceutical products Charleroi · balance sheet 223,918 €
- Lorophar Retail sale of pharmaceutical products Lincent · balance sheet 234,299 €
Frequently asked questions about Parry
What is the revenue of Parry?
Parry files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Parry?
In Belgium, the VAT number is the company number prefixed with BE: BE0880161865 for Parry, if the company is VAT-registered. Its company number (CBE) is 0880.161.865.
Where is the registered office of Parry?
According to the CBE register, the registered office of Parry is in 1030 Schaerbeek.
What is the equity of Parry?
At the close of the 2025 financial year, the equity of Parry amounts to -3,135 €, a solvency of -1.4% of total assets.
How many people work at Parry?
1.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Parry?
The register lists 1 active mandates at Parry. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Parry
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →